Back to Search Start Over

Exploiting mesoporous silica, silver and gold nanoparticles for neurodegenerative diseases treatment.

Authors :
Ribeiro TC
Sábio RM
Carvalho GC
Fonseca-Santos B
Chorilli M
Source :
International journal of pharmaceutics [Int J Pharm] 2022 Aug 25; Vol. 624, pp. 121978. Date of Electronic Publication: 2022 Jul 02.
Publication Year :
2022

Abstract

Neurodegenerative diseases (NDs) are considered public health problem characterized by neural loss causing cognitive and behavioral impairments. It is currently possible to use drugs capable of controlling the symptoms caused by these diseases. However, treatment is not able to prevent neural loss. In addition, poor solubility, low bioavailability due to the inability for crossing the blood-brain barrier (BBB) are described as the main limitations of the treatment. Nanotechnology involves the development of nanoscale drug delivery systems and they have been employed to optimize therapeutics face to several diseases treatment. In light of this, this review describes the highlights on the fabrication of nanotechnology-based drug delivery systems emphasizing mesoporous silica, gold and silver nanoparticles (MSNs, AuNPs and AgNPs, respectively) and their biological behavior for the treatment of Alzheimer's and Parkinson diseases (ADs and PDs, respectively).<br /> (Copyright © 2022 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-3476
Volume :
624
Database :
MEDLINE
Journal :
International journal of pharmaceutics
Publication Type :
Academic Journal
Accession number :
35792231
Full Text :
https://doi.org/10.1016/j.ijpharm.2022.121978